In three months, more than 12 cases, the pharmaceutical industry staged a "merger and acquisition" drama.

"Pharmaceutical Network Industry Dynamics" recently, with the "peptide industry" as the core of the national health key enterprise Yunhong Group announced that it will buy Wuhan Sixth Pharmaceutical Co., Ltd., Shanghai Anding Bio (Tong yin) Pharmaceutical Co., Ltd., Anyang Qiankang Pharmaceutical Co., Ltd., Anyang Qiankang and Pharmaceutical Chain Co., Ltd. four pharmaceutical companies.
public information shows that Yunhong Group Co., Ltd. was founded in 2013, is a focus on the large health industry enterprises, with molecular companies or domestic and foreign branches of more than 50.
2020, it will be officially listed on NASDAQ in New York.
It is learned that after the acquisition of equity, the company will actively develop the overall layout of the large health and biopharmaceutical peptide industry, on the basis of existing products for restructuring and integration, priority production of peptide home series of drugs and health care products, such as unified brand, design and logo, to create Yunhong Group biopharmaceutical technology series of products, seize the market commanding heights.
"mergers and acquisitions" is undoubtedly the hot word in the pharmaceutical industry in recent years.
, according to dandelion incomplete statistics, so far in May this year, there have been 12 pharmaceutical mergers and acquisitions.
, via bio-announcement, which also took place in August, stated that on August 8, 2020, via Biotech (Shanghai), an indirect whon-owned subsidiary of the company, entered into a share purchase agreement as a buyer.
Biotech (Shanghai) will acquire an 80% stake in Langhua Pharmaceuticals for RMB2.56 billion.
It is understood that this strategic integration will give full play to the business synergies between Via Bio and Longhua Pharmaceuticals in the research and development, design and production of the global pharmaceutical market, and will be of great strategic significance for Via Bio to integrate vertically in the industrial chain and expand into CDMO (Contract Research and Development Production Organization) business and establish an integrated one-stop drug service platform.
, Dongcheng Pharmaceuticals, Haizheng Pharmaceuticals, National Pharmaceuticals, Sanli Pharmaceuticals, Jinshi Ya Pharmaceuticals, Merya, Guangshengtang and other pharmaceutical companies disclosed the announcement, announced the merger plan.
its wholly-owned subsidiary Andico will acquire a 48.3084 percent stake in Mitsus Bio for $96.65 million in cash (corresponding to a registered capital of $9.4937 million).
data show that Mito Bio is the domestic head of molecular imaging pharmaceutical research and development outsourcing (MI-CRO) enterprises, can provide customers at home and abroad with drug screening, biological distribution, pharmacodynamics research, pharmacodynamic evaluation and other new drug research and development overall solutions and outsourcing technical services.
For the merger, Dongcheng Pharmaceuticals said that based on the needs of strategic planning and business development, the company acquired a part of Themi bio-part of the equity, using its characteristic tracer technology in molecular imaging technology advantages, accurate quantitative and qualitative determination of the target accuracy of new drugs and drug effectiveness, for the company's innovative drug decision-making and research and development pipeline strategic planning to lay the foundation.
at the same time, it will help to use the resources and experience of Rice Bio in the conversion of nuclear drugs to accelerate the company's new drug market speed.
In June, domestic pharmaceutical companies such as Tiansli, Beida Pharmaceuticals and Xinbang Pharmaceuticals announced a merger announcement, while Japanese drugmaker Takeda announced a $2.115 billion agreement to license seven of its psychiatric drugs to Nuurocrine Biosciences, including three for clinical phase projects such as schizophrenia and refractic depression.
, Shanghai Pharmaceuticals and Hainan Hai Pharmaceuticals announced a $144 million acquisition of Takeda's wholly-owned Swiss subsidiary, Takeda ChromeBete. Iligungs AG has a 100 per cent stake, indirectly holding a 26.34 per cent stake in Guangdong Tianpu Biochemical Pharmaceuticals Co., Ltd., which has issued a restructuring plan to buy 100 per cent of Qili Pharmaceuticals for more than 2.1 billion yuan.
fact, it is clear from the merger and acquisition objectives of some of the above-mentioned pharmaceutical companies, such as Dongcheng Pharmaceuticals, that the focus of pharmaceutical companies is accelerating the shift to innovative drugs.
industry pointed out that with the normalization of volume procurement, innovation has become the trend of the development of the pharmaceutical industry, in this context, pharmaceutical companies through increased investment in innovation and research and development, as well as through acquisitions and other ways in-depth layout.
.